bradykinin
Peptideexperimental
Bradykinin (BK) (from Greek brady- 'slow' + -kinin, kīn(eîn) 'to move') is a peptide that promotes inflammation. It causes arterioles to dilate (enlarge) via the release of prostacyclin, nitric oxide, and endothelium-derived hyperpolarizing factor and makes veins constrict, via prostaglandin F2, thereby leading to leakage into capillary beds, due to the increased pressure in the capillaries. Bradykinin consists of nine amino acids, and is a physiologically and pharmacologically active peptide of the kinin group of proteins. — Wikipedia
Clinical trial activity
11 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
1
Earliest trial started Nov 1, 1999 (NCT00160888)
Timeline
Indications
Approved for
Mechanism of action
- B1 bradykinin receptorAGONIST
BDKRB1 agonist
Chemistry & pharmacology
Loading structure…
SMILES
N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)O- Mol. weight
- 1060.23 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBradykinin ↗
- ChEMBLCHEMBL406291 ↗
Also known as
- bk
- bradykinin
- bradykinin
- bradykinin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03738878 | Phase 4 | Nov 15, 2018 | Vanderbilt University |
| NCT02189122 | N/A | Jul 1, 2014 | Vanderbilt University |
| NCT01413542 | N/A | Nov 1, 2011 | Vanderbilt University |
| NCT00780637 | N/A | Oct 1, 2008 | Vanderbilt University |
| NCT00780377 | N/A | Oct 1, 2008 | Vanderbilt University |
| NCT00685945 | N/A | Dec 1, 2007 | National Center for Research Resources (NCRR), National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Vanderbilt University |
| NCT00780481 | N/A | Jan 1, 2007 | Vanderbilt University |
| NCT00868855 | Phase 1 | Dec 1, 2003 | Northwestern University, Vanderbilt University |
| NCT00166166 | Phase 2 | Jul 1, 2002 | Emory University |
| NCT00004575 | Phase 1 | Feb 1, 2000 | National Heart, Lung, and Blood Institute (NHLBI) |
| NCT00160888 | Phase 1 | Nov 1, 1999 | University of Heidelberg |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vanderbilt University | Academic/Hospital | 8 | 8 | 3 | 2003 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 2 | 1 | 2 | 2000 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| National Center for Research Resources (NCRR) | Government | 1 | 0 | 1 | 2007 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2007 |
| Northwestern University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| University of Heidelberg | Academic/Hospital | 1 | 1 | 1 | 1999 |
7 organizations
Page 1 / 1